Bordetella Pertussis Colonisation Challenge Study

计划入组 80 人 · 首次发布于 2018 年 11 月 23 日

Establishing a Controlled Human Infection Model of Bordetella Pertussis

计划入组 79 人 · 首次发布于 2021 年 11 月 29 日

EUpertstrain 4 Study of Bordetella Pertussis Isolates

计划入组 265 人 · 首次发布于 2017 年 6 月 23 日

Bordetella pertussis toxoid antigen (formaldehyde inactivated)(Vaxelis)

Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)(Adacel, Boostrix, Infanrix, Kinrix, Pediarix, Hexyon)

Bordetella pertussis toxoid antigen (glutaraldehyde inactivated)(Adacel, Daptacel, Pentacel, Quadracel, Vaxelis)

Global Antibiotic Research & Development Partnership

Switzerland

Shionogi & Co., Ltd.

Japan

Acurx Pharmaceuticals

United States

Trinity College Dublin Develops Needle-Free Nasal Vaccine That Blocks Whooping Cough Transmission

Roche Receives FDA Clearance for 15-Minute Point-of-Care Bordetella PCR Test

ILiAD and hVIVO Partner for Phase 3 Human Challenge Trial of BPZE1 Pertussis Vaccine